Key takeaways
- Most BPC-157 research is in animals and cells: 35 of the 36 studies in a 2025 systematic review of musculoskeletal research were preclinical, and 6AM Research grades its evidence Preclinical.
- The rat tendon and muscle studies measured walking function, the load tissue held before failing, and tissue under the microscope; most come from one research group, and none is evidence of an effect in people.
- We found six small published studies that gave BPC-157 to people, most without a control group; the only randomised, placebo-controlled data are conference abstracts from 2002 to 2005 (PubMed and FDA’s 2026 review, 21 Nov 2026).
- A 2026 systematic review rated the certainty of the human evidence “very low”, and FDA staff found “insufficient clinical safety information to characterize the safety profile”.
- ClinicalTrials.gov lists four records that give BPC-157; none had posted results on 21 November 2026, and a placebo-controlled phase 2 trial is recruiting.
01BPC-157 claims at a glance: how far the research has gone
How far the research on BPC-157 has gone, dated 21 November 2026. 6AM Research grades its evidence Preclinical on the BPC-157 guide, because most of it sits in animals and cells.
Bar lengths show order only, not a score, and a row with no qualifying study is drawn at 0%. The rows on people count the six published studies we found that gave BPC-157 to people: four without a control group, and two randomised studies known only from conference abstracts.
Source: Vasireddi et al., HSS J, 2025; FDA’s 2026 review of BPC-157; PubMed and ClinicalTrials.gov searches of 21 Nov 2026.
02What did the main BPC-157 animal and cell studies measure?
If you searched “bpc 157 benefits”, the plain version is this: the studies behind the claims measured specific things, mostly in rats. Three kinds of study, and the model each used; each card names what was measured, not what to expect.
Achilles tendon cut in rats
Walking function, scored daily, and up to day 14 the load the tendon held before failing and its tissue under the microscope. The abstract gives no number of rats.
Thigh muscle cut in rats
Over 72 days: the load the muscle held before failing, walking and motor function, and its tissue under the microscope.
Rat tendon pieces and cells in a dish
How far cells grew out of the tissue, how many survived chemical stress, and how far they moved. A cell result is not evidence of an effect in people.
One research group, mostly. The 2003 and 2006 tendon studies, the 2006 muscle study and a 2008 study of crushed calf muscle all come from the department of pharmacology at the University of Zagreb. Human data on these measures is lacking.
A second group, 2026 (T3). Researchers in Türkiye cut and repaired the Achilles tendon in 32 male rats, eight per group, given BPC-157, TB-500, both or neither. At four weeks they measured the load the tendon held before failing and scored the tissue. The authors call it an “exploratory rat model study”.
03Study by study: model, sample, measure, limit
One row per study cited here. Rows name what was measured, not what to expect.
| Area and what was measured | Study | Model and n | Tier | Limit |
|---|---|---|---|---|
| Tendon: walking function, load to failure, tissue under the microscope | Staresinic et al., 2003 | Rats with a cut Achilles tendon; n not in the abstract | T3 | No measure in people |
| Tendon to bone: walking function, load to failure, collagen staining | Krivic et al., 2006 | Rats with the tendon cut from the heel bone; n not in the abstract | T3 | Same group |
| Muscle: load to failure, walking and motor function, tissue | Staresinic et al., 2006 | Rats with a cut thigh muscle; 72 days; n not in the abstract | T3 | Same group |
| Muscle: tissue, function, blood enzymes | Novinscak et al., 2008 | Rats with a crushed calf muscle; 14 days; n not in the abstract | T3 | Same group |
| Tendon cells: outgrowth, survival under stress, migration | Chang et al., 2011 | Rat tendon pieces and tendon cells in culture | T4 | Cells only; not evidence of an effect in people |
| Tendon after repair: load to failure, tissue scores, collagen types I and III | Biçer et al., 2026 | 32 male rats, 8 per group: BPC-157, TB-500, both or neither; 4 weeks | T3 | The authors call it exploratory |
| People, healthy volunteers: tolerability, blood levels | Veljaca et al., 2002 and 2003 | 32 randomised, 24 given BPC-157, the rest placebo | T2 | Conference abstracts only, summarised by FDA staff |
| People, patients: among the measures, a disease-activity score and blood levels | Ruenzi et al., 2005 | 53 randomised to BPC-157 or placebo, 46 completed | T2 | Conference abstract only; FDA staff found the data inadequate |
T2 is small or uncontrolled human research, T3 is animal studies and T4 is cell studies: how we grade evidence. The two abstract-only studies are known from FDA’s 2026 review. Material sold online is not the product these studies tested.
04Has BPC-157 been tested in people?
In small studies, and not in a peer-reviewed randomised trial (PubMed, 21 November 2026). In the published literature we found six studies that gave BPC-157 to people, 118 participants in all. Reports made to FDA are a separate record; they show no cause and no rate.
- 2002–2003Healthy-volunteer abstracts
Conference abstracts, summarised by FDA staff, describe a randomised, placebo-controlled study in 32 healthy volunteers that measured tolerability and blood levels.
- 2005A patient study, abstract only
A randomised, placebo-controlled study of 53 patients, 46 of whom completed it. FDA staff found its data “inadequate to support the efficacy and safety” of BPC-157 in that setting.
- 2021–2025Three small studies without a control group
A chart review with a phone survey of 16 patients (2021), a single-arm study of 12 women (2024) and a two-person safety pilot (2025). All three list the same first author.
- Sep 2026A three-patient case report
Three patients received BPC-157 together with TB-500 and other agents, with no control group. The authors write that causality “cannot be established”.
- 2026A systematic review
Reviewing the three full papers, 30 people in all, the authors judged each of poor methodological quality and rated the certainty of the evidence “very low”.
- Nov 2026Registered, no results
ClinicalTrials.gov lists four records that give BPC-157, none with posted results. One, NCT07437547, is a placebo-controlled phase 2 trial planned for 120 patients aged 18 to 45, recruiting since February 2026.
The phase 2 trial asks whether time to return to sport, and the size of a muscle injury on MRI, differ from placebo. Every study, with its design and size: BPC-157 human studies.
05What did FDA staff and independent reviewers conclude?
FDA, on effectiveness. Reviewing BPC-157 for the list of substances pharmacies may compound with, FDA staff found “a lack of evidence to support the effectiveness” of BPC-157 for the use nominated to them. In a search of globalEDGE they found it in no approved product in any country.
FDA, on animal studies. FDA staff noted that rat studies have reported effects of BPC-157-related substances in models of induced gut, liver and fistula injury. They added that the relationship between amount and response has “not been established”, that the molecular targets “have not been identified” and that the mechanisms “remain poorly understood”, so the plausibility of those effects is “difficult to assess”. They judged the animal toxicity studies “too limited in scope and duration” to inform safety.
FDA, on safety in people. FDA staff concluded that there is “insufficient clinical safety information to characterize the safety profile” of BPC-157.
Independent reviews. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons, searching to June 2026, found the human musculoskeletal evidence “limited to one small retrospective uncontrolled case series without validated outcome measures”, and no “controlled human orthopaedic efficacy evidence” for BPC-157, thymosin β4 or TB-500.
Where BPC-157 stands with regulators in the US, UK and Australia, and in sport: the BPC-157 guide. What has been reported about adverse events: BPC-157 side effects.
06What we don’t know about BPC-157
Whether any effect shows up in people
We found no peer-reviewed randomised trial of BPC-157 in people (PubMed, 21 Nov 2026), and the four registered studies have posted no results.
Whether rat results carry over
Most tendon and muscle studies come from one group, in rats. FDA staff write that the link between amount and response has not been established, and that the molecular targets have not been identified.
How the body handles it
In the two studies that measured blood levels, FDA staff report that BPC-157 was not detected, or mostly below the assay’s limit. Both are known only from conference abstracts.
Which molecule a vial holds
FDA gives BPC-157 free base a molecular weight of 1419.5 g/mol. The mass result on a lot’s report is the line that shows whether a sample matches.
How to find that line on a lab report: how to read a COA. How a mass result identifies a peptide: mass spectrometry explained.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.